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In chronic respiratory disease, matrix metalloproteinases (MMPs) contribute to pathological tissue destruction when expressed in
excess, while tissue inhibitors of metalloproteinases (TIMPs) counteract MMPs with overexpression leading to fibrosis formation.
They may be out of balance in equine pneumopathies and serve as biomarkers of pulmonary inflammation. We hypothesized
that MMPs and TIMPs correlate to clinical findings and bronchoalveolar lavage fluid cytology in different equine chronic
pneumopathies. Using a scoring system, 61 horses were classified controls as free of respiratory disease (𝑛 = 15), recurrent airway
obstruction (RAO, 𝑛 = 17), inflammatory airway disease (IAD, 𝑛 = 18), or chronic interstitial pneumopathy (CIP, 𝑛 = 11).
Zymography and equine MMP and TIMP assays were used to detect MMP-2, MMP-8, MMP-9 as well as TIMP-1, and TIMP-2
in BALF supernatant. MMP-2, TIMP-1, and TIMP-2 concentrations were significantly increased in RAO and IAD compared to
controls. MMP-9 concentration and MMP-8 activity evaluated by fluorimetry were significantly increased in RAO, IAD, and CIP.
These results were confirmed by zymography for MMP-2 and MMP-9 activity in 52 horses. In conclusion, MMPs and TIMPs
correlate well with clinical and cytologic findings. These findings support the usefulness of MMPs, TIMPs, and their ratios to
evaluate the severity of respiratory disease and may help to identify subclinical cases.
1. Introduction
The extracellular matrix (ECM) represents the scaffold that
supports the alveolar wall and has a major impact on
lung architecture, homeostasis, and function.The pulmonary
ECM underlays a continuous turnover; a dynamic equilib-
rium between synthesis and degradation of the ECM ismain-
tained for physiological balance. This balance is controlled
by synthesis and deposition of ECM components, proteolytic
degradation of ECM by matrix metalloproteinases (MMPs),
and inhibition ofMMP activity by specific tissue inhibitors of
matrix metalloproteinases (TIMPs) [1–3]. In health, MMPs
degrade the ECM to allow normal tissue repair, but in
chronic inflammation they contribute to pathological tissue
destruction when expressed in excess [4]. Thus, it has been
suggested that MMPs can either protect against or contribute
to pathology in inflammatory processes by exacerbation of
aberrant lung remodeling [5–7]. ECM degradation results in
destruction of interstitial collagen and release of degraded
collagen fragments, which results in neutrophil influx with
the production of chemoattractants [8]. In chronic res-
piratory disease, remodeling results in decreasing airway
lumen, increased smoothmusclemass, peribronchial fibrosis,
epithelial cell hyperplasia, and impaired airway function [9–
11]. Regulation of remodeling may be a key for developing
new therapeutics and disease management [2].
Matrix metalloproteinases (MMPs) were first described
over 50 years ago by Gross and Lapiere [12]. Collagenolytic
MMP-8 was increased in tracheal epithelium lining fluid
(TELF) of RAO affected horses [13]. Immunoreactivity of
collagenasesMMP-8 andMMP-13was significantly increased
in TELF of horses with RAO, compared to healthy horses, and
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Markedly increased elastolytic activity in TELF was also
found in RAO, suggesting participation of elastases (MMP-
2, MMP-3, MMP-7, MMP-9, MMP-10, and MMP-12) [15].
Other authors found no difference in pro-MMP-2 compared
to healthy horses and suggested that MMP-2 may repre-
sent a housekeeping proteinase involved with normal tissue
remodeling [16]. Previously it has been described that the
molecular weight of pro-MMP-2 is 65–75 kDa and that of
lower molecular weight gelatinolytic species is below 50 kDa
[17]. In horses, MMP-9 is found elevated in RAO affected
horses. In TELF andBALFMMP-9-related gelatinase-activity
was represented by 5 bands: highmolecular weight gelatinase
complex (above 110 kDa), pro-MMP-9 (90–110 kDa), and
active MMP-9 (75–85 kDa) [17]. In tracheal aspirates of RAO
affected horses, mainly high molecular weight bands (150–
210 kDa) and 90–110 kDa bands were found in symptomatic
disease phases compared to healthy horses [16]. MMP-9
represents the largest and complex member of MMPs that
is present in low quantities in the healthy adult lung but
much more abundant in several lung diseases, including
asthma, idiopathic pulmonary fibrosis, and RAO [18]. BALF
gelatinolytic MMP activity in RAO affected horses increases
as early as 5 hours after natural challenge and correlates with
the BALF neutrophil counts [18, 19].
Tissue inhibitors ofmetalloproteinases are specific inhibi-
tors of MMPs that bind to MMPs and inhibit their enzymatic
activity. Four TIMPs have been identified including TIMP-1,
TIMP-2, TIMP-3, and TIMP-4 and inhibit all MMPs tested
[20, 21]. In human COPD, increased MMP-9 and TIMP-1
concentrations were detected in plasma and BALF [22].
TIMP-1 is the most widely distributed and acts on all
active MMPs. A higher concentration of TIMP-1 was found
in human BALF of asthmatic patients compared to healthy
controls; thus it might be a better marker for mild asthma
[23]. Also, high levels of TIMP-1 are associatedwith increased
airway fibrosis. In addition, the molar concentration of
TIMP-1 often exceeds the concentrations of MMP-9 and
other MMPs [24]. These findings suggest that although
TIMP-1 protects airway tissue from enhanced MMP activity,
its increase may also be pathogenic and lead to enhanced
airway fibrosis.
TIMP-2 appeared to be effective in preventing ECMdam-
age by inhibition of MMP-2 and related proteolytic activity.
Additionally, it serves as a target for therapy as reduced airway
inflammation and hyperresponsiveness were observed after
the administration of recombinant TIMP-2 in the bronchial
tree [25].
In addition to MMP and TIMP concentrations, MMP :
TIMP ratios have raised increasing interest in human asthma
and COPD. They have been found to be even more sensitive
biomarkers than MMPs and TIMPs. To our knowledge,
TIMPs and MMP : TIMP ratios in equine pulmonary disease
have not been studied so far.
While the role of MMPs in RAO has been studied inten-
sively in the horse, not much is known about other chronic
respiratory diseases leading to exercise insufficiency and
therefore representing a major economic problem in the
horse industry. We hypothesized that MMP-2, MMP-8 and
MMP-9 as well as TIMP-1 and TIMP-2 concentrations
correlate with clinical and cytologic data and increase in
different forms of chronic pneumopathy including RAO,
inflammatory airway disease (IAD), and chronic interstitial
pneumopathy (CIP). We also suspected that MMP : TIMP
might be valuable biomarkers in equine disease.
2. Materials and Methods
2.1. Preparticipation Examination. A total of 64 horses were
examined, of which 15 had no clinical signs or history of
respiratory disease and 49 were presented to the clinic with
a history of chronic lower airway disease. Sampling of horses
affected by respiratory disease was not classified as animal
experiments by the State Office of Health and Social Affairs
Berlin (LaGeSo); sampling of control horses was approved
(reference number L0294/13).The owners gave permission to
involve their horses in the study.
The preparticipation examination included anamnesis
documentation, clinical examination, exercise test, blood
gas analysis, bronchoscopy, BALF cytology, and thoracic
radiography. A modified clinical score system including
endoscopy results, parameters of gas exchange, and BALF
cytology was used, shown in Table 1 [26, 27]. Additionally,
results of thoracic radiography were included to classify
horses as free of respiratory disease (controls), recurrent
airway obstruction in exacerbation (RAO), inflammatory
airway disease or RAO in remission (IAD), and chronic
interstitial pneumopathy (CIP) or were excluded from the
study, if they could not be assigned to these groups. In detail,
groups were defined as follows:
(i) Controls: no history of respiratory disease, clinical
score <2, no tracheal secretions, low cellular density
and neutrophils ≤ 8% in BALF, AaDO
2
≤8mmHg,
and exclusion of acute signs of infection (leukocyto-
sis, fever, and depression).
(ii) RAO: history of recurrent cough or dyspnea, clinical
score >6, high amount or viscosity of tracheal secre-
tions, high cellular density and neutrophils ≥25% in
BALF, AaDO
2
>8mmHg, and exclusion of acute
signs of infection (leukocytosis, fever, and depression)
according to Robinson [28].
(iii) IAD: history of cough or exercise insufficiency, clin-
ical scores 2–6, low to moderate amount or viscosity
of tracheal secretions, increased cellular density and
neutrophils ≥8% or mast cells ≥2% or eosinophils
≥0.1% in BALF, and exclusion of acute signs of infec-
tion (leukocytosis, fever, and depression) according to
Coue¨til et al. [29].
(iv) CIP: history of exercise insufficiency, clinical score 2–
6, low to moderate amount or viscosity of tracheal
secretions, increased cellular density and ratio of
macrophages: neutrophils ≥2.5 : 1 in BALF, increased
interstitial opacity of thoracic radiographs, and exclu-
sion of acute signs of infection (leukocytosis, fever,
and depression) according to Dieckmann et al.
[30].
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Table 1: Clinical scoring system, modified from Ohnesorge et al. (1998) [26] and Gehlen et al. (2008) [27].
Score Max. points
(1) Cough induction
No cough after manual compression of larynx 0
1Coughing during manual larynx compression 1
Very frequent coughing 1
Spontaneous coughing 1

















Significantly increased secretions with moderate viscosity 1
2Highly increased secretions with high viscosity 2
















2.2. BALF Collection and Processing. During endoscopy,
20mL of 2% lidocaine (Lidocaine, Bela-Pharm GmbH,
Vechta, Germany) was infused around the tracheal bifurca-
tion.The catheter (Silicone Bronchoalveolar Lavage Catheter
300 cm, SmithsMedical ASD, Inc., USA) was wedged into the
bronchus by mean of an air balloon. Five hundred milliliters
of prewarmed phosphate buffered saline (phosphate buffered
saline, Lonza, Verviers, Belgium) was infused as recom-
mended by the International Workshop on Equine Chronic
Airway Disease [28] and immediately aspirated.
BALF was divided into 2 portions for cytological and
biochemical examination. After centrifugation (Table Top
Refrigerated Centrifuge Hermle Z326K, Hermle Labortech-
nik GmbH, Germany) at 1500 rpm for 10min at 4∘C the cell-
free supernatant was stored at −80∘C until being assayed.
Cytology was performed using Wright-Giemsa staining and
counting 500 cells at 500x magnification.
2.3. Gelatin Zymography (MMP-2 and MMP-9). Zymog-
raphy was performed (gelatin zymogram gels (Life Tech-
nologies, USA); electrophoresis device XCell, Novex Exper-
imental Technology, Japan) according to the manufacturer’s
manual. Human MMP-2 and MMP-9 controls (recombinant
human MMP-2, USCN Life Science, Inc., China) were used
together with amulticolor broad protein range protein ladder
(Spectra Multicolor Broad Range Protein Ladder, Thermo
Scientific, Rockford, USA) as control on each gel. Also, a
sample of a control horse was applied to each gel to compare
the signals to affected horses. Gels were scanned for digital
analysis by densitometry using digital image analyzing soft-
ware (ImageJ v1.47,Wayne Rasband, NIH, USA) for objective
quantification of bands and the results were presented based
on peak area [31].
2.4. ELISA of MMP-2, MMP-9, TIMP-1, and TIMP-2. The
ELISAs used in this study were equine specific sandwich
enzyme immunoassays for quantification ofMMP and TIMP
concentrations (equine MMP-2 kit, USCN Life Science,
Inc., China; equine MMP-9 kit, USCN Life Science, Inc.,
China; equine TIMP-1 kit, USCN Life Science, Inc., China).
Standards and samples were set up in duplicate according to
the manufacturer’s protocol. The absorbance was measured
with an ELISA microplate reader (equine TIMP-2 kit, USCN
Life Science, Inc., China) at 450 nm immediately. Calculation
of the unknown sample concentration was made by inverted
standard curve using the Excel software program.
2.5. Fluorimetry MMP-8 Assay. The MMP-8 assay (ELISA
microplate reader, BioRad Laboratories, USA) was per-
formed according to the manufacturer’s protocol. Negative
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Table 2: Results of clinical examinations. ∗ shows significant increase to controls at 𝑝 < 0.05 and ∗∗ significant increase in RAO compared
to IAD and CIP. RAO: recurrent airway obstruction, IAD: inflammatory airway disease, and CIP: chronic interstitial pneumopathy.
Controls (𝑛 = 15) RAO (𝑛 = 17) IAD (𝑛 = 18) CIP (𝑛 = 11)
Endoscopy score 0 ± 0 1.82 ± 0.39∗ 1.17 ± 0.71∗ 0.91 ± 0.7∗
BAL score 0 ± 0 3 ± 0∗ 1.39 ± 1.04∗ 0.45 ± 0.69
Blood gas score 0.2 ± 0.4 0.76 ± 0.75∗ 0.17 ± 0.38 0.36 ± 0.81
Total exam score 0.27 ± 0.46 8.12 ± 2.23∗,∗∗ 3.88 ± 1.41∗ 2.36 ± 2.66∗
Table 3: Results of endoscopic examination. ∗ shows significant increase to controls at 𝑝 < 0.05. RAO: recurrent airway obstruction, IAD:
inflammatory airway disease, and CIP: chronic interstitial pneumopathy.
Amount of secretions Viscosity of secretions Tracheal bifurcation
Controls (𝑛 = 15) 0.47 ± 0.64 0.4 ± 0.51 0.25 ± 0.45
RAO (𝑛 = 17) 3.5 ± 0.63∗ 3.88 ± 0.5∗ 1.36 ± 1∗
IAD (𝑛 = 18) 2 ± 1.33∗ 2.33 ± 1.4∗ 1.33 ± 0.82∗
CIP (𝑛 = 11) 2 ± 1.2∗ 1.8 ± 1.2∗ 1.56 ± 0.88∗
controls containing assay buffer and positive controls using
recombinant human purified MMP-8 were included.
2.6. Statistical Analysis. Datawere statistically analyzed using
SPSS (Sensolyte 520 MMP-8 Assay Kit, Anaspec, Inc., Fer-
mont, USA) and expressed as mean ± standard deviation
(SD). The data were tested for normal distribution using
the Shapiro Wilks Test. While some data were found to be
normally distributed, otherwas not, sowe preferred nonpara-
metric tests for the whole data. The level of significance was
set at 𝑝 < 0.05.
Kruskal Wallis 𝐻 test was used to compare between
controls and different disease groups followed by post hoc
testing using Mann-Whitney 𝑈 Test for 2-group comparison
to determine intergroup differences.
Spearman rank correlation coefficients were calculated
between clinical examination scores and blood gas scores
and between these variables and the total examination score,
neutrophil percentages,MMP-2,MMP-9 concentrations, and
MMP-8 activity. The Spearman correlation coefficients were
interpreted using the scale provided by Salkind, where the
values between 0.8 and 1.0, 0.6 and 0.8, 0.4 and 0.6, 0.2
and 0.4, and 0.0 and 0.2 were defined as very strong,
strong, moderate, weak, and very weak or no relationship,
respectively [32]. The same was performed for calculated
MMP : TIMP ratios.
3. Results
According to the results of the clinical examination, the 64
horses (35 geldings, 29 mares, aged 12.74 ± 5.25 years, BDW
473.79 ± 5.26 kg) presented for participation in this study
were classified as follows: 15 horses (23.4%) were classified as
free of respiratory disease (controls), 17 (26.6%) as RAO in
exacerbation, 18 (28.1%) as RAO in remission or IAD, and
11 (17.2%) as CIP and 3 horses (4.7%) suffered from acute
respiratory infections and were excluded. The overall results
of the clinical examinations are presented in Table 2.
3.1. Endoscopy. The results of the endoscopic examination
including the amount and viscosity of secretions and the
tracheal bifurcation appearance were scored according to
Dieckmann and Deegen [33] and Gerber et al. [34] and
included into a modified overall clinical score [26, 27]. The
results are presented in Table 3.
3.2. Pulmonary Function. The results of arterial blood gas





significantly increased in RAO but not in other disease
groups.
3.3. BALF Cytology. Percentages of macrophages, lympho-
cytes, mast cells, and in particular neutrophils were highly
and significantly different between controls and different
disease groups (Table 5). BALF neutrophils percentage (refer-
ence range 0–8%)was significantly increased in RAO (60.68±
21.59%), IAD (15.64 ± 8.19%), and CIP (8.73 ± 5.71%)
compared to controls (3.02± 2.41%). Also, BALF neutrophils
percentage was significantly increased in RAO compared to
IAD and CIP.
3.4. MMP-2 ELISA. In RAO (5.21 ± 0.77 ng/mL) and IAD
(7.67 ± 15.5 ng/mL) highly significant increases in MMP-
2 concentrations were found compared to controls (2.49 ±
0.83 ng/mL). MMP-2 was not increased in CIP (2.81 ±
0.34 ng/mL). Horses diagnosed with IAD showed a highly
significant increase compared to RAO and CIP.
3.5. MMP-9 ELISA. Obvious differences between disease
groups were detected. Highly significant increases in MMP-
9 concentration were found in RAO (433.34 ± 89.05 pg/mL),
IAD (312.06 ± 23.92 pg/mL), and CIP (263.2 ± 23.85 pg/mL)
compared to controls (176.29 ± 60.22 pg/mL). In RAO
a highly significant increase compared to IAD and CIP
was evident. Other intergroup differences were not found
significant.
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Table 4: For arterial blood gas analysis, the results are expressed as mean ± SD. ∗ shows significant difference to controls at 𝑝 < 0.05. RAO:








Controls (𝑛 = 15) 43.87 ± 2.53 101.95 ± 6.18 0.52 ± 1.03
RAO (𝑛 = 17) 43.63 ± 4.76 87.9 ± 12.15∗ 10.91 ± 9.3∗
IAD (𝑛 = 18) 43.75 ± 3.02 94.98 ± 7.38 5.17 ± 8.03
CIP (𝑛 = 11) 44.19 ± 3.24 94.23 ± 9.4 5.55 ± 8.5
Table 5: For BAL cytology, the results of cell percentages are expressed as mean ± SD. ∗ shows significant differences to controls at 𝑝 < 0.05,
∗∗ significant increase in RAO compared to IAD and CIP, and ∗ ∗ ∗ significant decrease in RAO compared to IAD and CIP. RAO: recurrent
airway obstruction, IAD: inflammatory airway disease, and CIP: chronic interstitial pneumopathy.
Macrophages [%] Lymphocytes [%] Neutrophils [%] Eosinophils [%] Mast cells [%]
Controls (𝑛 = 15) 56.48 ± 4.75 38.15 ± 6.41 3.02 ± 2.41 0.13 ± 0.27 2.22 ± 2.06
RAO (𝑛 = 17) 19.64 ± 12.07∗,∗∗∗ 18.66 ± 12.16∗ 60.68 ± 21.59∗,∗∗ 0.27 ± 0.35 1.16 ± 1.22
IAD (𝑛 = 18) 43.78 ± 12.98∗ 34.63 ± 13.65 15.64 ± 8.19∗ 1.95 ± 3.9 3.8 ± 3.21
CIP (𝑛 = 11) 50.83 ± 15.46 34.47 ± 11.87 8.73 ± 5.71∗ 0.95 ± 0.92 5.03 ± 4.34
3.6. MMP-8 Activity. MMP-8 activity showed significant
differences between all groups. In RAO (21,802.03 ±
21,047 RFU), IAD (5,366.17 ± 1,434 RFU), and CIP
(3,800.36 ± 403RFU) significant increases were found com-
pared to controls (3,556.63 ± 176RFU). Intergroup analysis
revealed highly significant increases in MMP-8 activity in
RAO compared to IAD and CIP. A significant increase was
also found in IAD compared to CIP.
3.7. TIMP-1 ELISA. Highly significant increases in TIMP-1
concentrations were found in RAO (328.19 ± 62.83 pg/mL)
and IAD (308.92 ± 8.24 pg/mL) compared to controls
(117.54 ± 45.62 pg/mL). Intergroup differences were not
significant.
3.8. TIMP-2 ELISA. TIMP-2 concentrations were also highly
significantly increased in groups RAO (27.75 ± 5.08 ng/mL)
and IAD (25.42 ± 1.38 ng/mL) compared to controls (18.06 ±
2.37 ng/mL). Intergroup differences were not significant.
3.9. MMP-TIMP Ratios. Significant differences were found
for RAO in MMP-9/TIMP-2, MMP-8/TIMP-1, and MMP-
8/TIMP-2 ratios, for IAD in MMP-2/TIMP-2 and MMP-
8/TIMP-1 ratios, and for CIP in the MMP-8/TIMP-1 ratio.
A concluding summary of all MMP- and TIMP-
measurements is presented in Table 6 and for MMP/TIMP
ratios in Table 7.
3.10. Gelatin Zymography. Gelatin zymography was per-
formed on 52 BALF samples from controls (𝑛 = 13), RAO
(𝑛 = 17), IAD (𝑛 = 14), and CIP (𝑛 = 8) affected horses.
Gelatinolytic activity bands were detected at about 70 kDa for
MMP-2 (pro-MMP-2) and at 100 and 140 kDa for MMP-9,
respectively (pro-MMP-9 and high molecular weight forms).
An example of a zymographic gel is shown in Figure 1.
Based on peak areas, high molecular weight bands of
MMP-9 showed significant differences between groups. In
Figure 1: Gelatin zymography of MMP-2 and MMP-9. Examples of
healthy controls (group I), RAO (group II), IAD (group III), andCIP
(group IV).The 70 kDa bands are representative of pro-MMP-2 and
those at 140 kDa are representative of high molecular weight MMP-
9 (arrow) as checked in a comparison of protein marker and human
MMP-2 and MMP-9 (data not shown).
RAO (10,967.31 ± 9,530.07) highly significant increases in
peak areas were found compared to controls (619.29 ±
996.32) and also showed a highly significant increase com-
pared to IAD (1,832.16 ± 2,111.29) and CIP (864.06 ± 767.93).
Other intergroup differences were not found significant.
Digital analysis for MMP-2 was based on bands of the
gelatinolytic pro-MMP-2. Bands showed highly significant
differences between RAO (17,288.53 ± 8,927.59) and IAD
(3,530.94±2,894.15) compared to controls (1,114.76±672.72).
Peak areas were significantly increased in RAO compared to
IAD andCIP (2,799.45±2,592.28, Figure 1). Other intergroup
differences were not significant.
3.11. Correlation of MMPs, TIMPs and Clinical Score. The
total clinical examination score showed a positive correlation
with the concentrations of MMP-2 (𝑟 = 0.75), MMP-8
(𝑟 = 0.77), MMP-9 (𝑟 = 0.79), TIMP-1 (0.65), TIMP-2
(0.72), MMP-8 : TIMP-1 (0.76), and MMP-8 : TIMP-2 ratio
(0.90). Also, a positive correlation was found with the MMP-
2 (𝑟 = 0.80) and MMP-9 (𝑟 = 0.71) activity measured by
gelatin zymography. All of these correlations had a level of
significance of 𝑝 < 0.01.
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Table 6: MMP-2, MMP-9, TIMP-1, TIMP-2 ELISA, andMMP-8 fluorimetry measurements.The results are expressed as mean ± SD. ∗ shows
significant increases to controls at 𝑝 < 0.05, ∗∗ significant increase in IAD compared to RAO and CIP, and ∗∗∗ significant increase in RAO
compared to IAD andCIP. RAO: recurrent airway obstruction, IAD: inflammatory airway disease, and CIP: chronic interstitial pneumopathy.
MMP-2 [ng/mL] MMP-9 [pg/mL] MMP-8 [RFU] TIMP-1 [pg/mL] TIMP-2 [ng/mL]
Controls (𝑛 = 15) 2.49 ± 0.83 176.29 ± 60.22 3,556.63 ± 176 117.54 ± 45.62 18.06 ± 2.37
RAO (𝑛 = 17) 5.21 ± 0.77∗ 433.34 ± 89.05∗,∗∗∗ 21,802.03 ± 21,047∗,∗∗∗ 328.19 ± 62.83∗ 27.75 ± 5.08∗
IAD (𝑛 = 18) 7.67 ± 15.5∗,∗∗ 312.06 ± 23.92∗ 5,366.17 ± 1,434∗ 308.92 ± 8.24∗ 25.42 ± 1.38∗
CIP (𝑛 = 11) 2.81 ± 0.34 263.2 ± 23.85∗ 3,800.36 ± 403∗ 205.47 ± 97.63 21.19 ± 2.45
Table 7: MMP : TIMP ratios. ∗ shows significant differences to controls at 𝑝 < 0.05. RAO: recurrent airway obstruction, IAD: inflammatory
airway disease, and CIP: chronic interstitial pneumopathy.
MMP-2 : TIMP-1 MMP-2 : TIMP-2 MMP-9 : TIMP-1 MMP-9 : TIMP-2 MMP-8 : TIMP-1 MMP-8 : TIMP-2
Controls (𝑛 = 15) 0.021 0.137 1.500 9.761 30.259 196.934
RAO (𝑛 = 17) 0.016 0.188 1.320 15.62∗ 66.431∗ 785.668∗
IAD (𝑛 = 18) 0.025 0.302∗ 1.010 12.28 17.37∗ 211.100
CIP (𝑛 = 11) 0.014 0.103 1.281 12.421 18.496∗ 179.35
3.12. Correlations of MMPs, TIMPs and BALF Cytology. BAL
neutrophil percentages showed a positive correlation with
the concentrations of MMP-2 (0.77), MMP-8 (0.76), MMP-9
(0.81), TIMP-1 (0.65), TIMP-2 (0.71),MMP-8 : TIMP-1 (0.90),
andMMP-8 : TIMP-2 ratio (0.98). Also, a positive correlation
was found with theMMP-2 (0.78) andMMP-9 (0.67) activity
measured by gelatin zymography. All of these correlations
had a level of significance of 𝑝 < 0.01.
4. Discussion
In horses, collagenolytic and elastolytic MMPs in pulmonary
secretions have been shown to increase during RAO [13–16].
In the present study, increased concentrations were found
not only in RAO but also in IAD and chronic interstitial
pneumopathies by semiquantitative and quantitative mea-
surements and were highly correlated with the results of
the clinical examinations and BALF cytology. TIMP concen-
trations were also increased in RAO and IAD but not in
CIP. Healthy horses seem to have minimal gelatinolytic and
collagenolytic activities, as MMP activity is physiologically
balanced byTIMPs. An imbalance betweenMMPexpression,
activation, and inhibition is associatedwith tissue destruction
in inflammatory lung diseases.
In the present study, MMP-2 and MMP-9 were identified
using gelatin zymography as described previously in equine
RAO [13, 17]. Human MMP markers served as controls due
to unavailability of the purified equine protein. Although
densitometrywas used for quantification of the bands and the
results were calculated based on peak area [31], we also aimed
for direct quantitative measurements using equine ELISA
kits. Quantification revealed the highest MMP-8 and MMP-
9 activities in RAO, but activities in IAD and CIP were also
significantly increased compared to controls.
In a study on tracheal epithelium lining fluid, the concen-
tration of autoactive collagenase was approximately 7 times
greater in RAO [14].The authors concluded that collagenases
are also involved in airway remodeling during exacerbation.
Several studies have shown that MMP-9 is the main MMP
present in the airways of RAO-susceptible horses following
inhalation of hay dust or its components [19, 35, 36].
In unison with previous studies [15–17], our results of this
study support the role of MMP-9 in RAO but also suggest
a role of collagenases in equine IAD and CIP. The high
positive correlations of MMPs and neutrophil percentages
in BALF suggest these cells to be the origin of MMPs,
in particular MMP-9, in RAO. Much debate exists on a
possible precursor role of IAD for the development of RAO
[29]. Increased MMP-8 activity in both groups may further
support this theory. In addition, it seems possible that CIP
may develop from IAD, which has a high prevalence in young
sports horses, while RAO and CIP are more common in
older individuals. In our study, we also found a correlation
of MMP-8 concentrations and neutrophil percentage in
BALF samples. Increased collagenase activity in lungs of
humans with emphysema and bronchiectasis is suspected
as a result of MMP-8 activity [37, 38]. All immunoreactive
forms ofMMP-8 detected inTELF sampleswere also detected
in equine neutrophil lysate. Therefore, neutrophil-derived
MMP-8 species were suggested to be the cause of the
MMP-8 immunoreactivity detected in TELF samples [14].
Immunoreactivity for MMP-8 in TELF from RAO horses
was approximately 13 times greater than in controls [14]. The
factor between RAO horses and controls is even larger in our
study and there were also significant increases in IAD and
CIP. Nevertheless, the highest concentrations were measured
in RAO with significant differences to the other groups.
The role of MMP-2 is of controversy in the literature.
MMP-2 has been considered to be constitutively expressed
[14, 35] and therefore its induction in inflammation has
rarely been detected. Our results support this theory, as
zymography only revealed bands of pro-MMP-2 in most
cases. The MMP-2 ELISA also showed the highest values
in horses suffering from IAD, which is characterized by a
lower grade of inflammation and pulmonary dysfunction
compared to RAO in exacerbation. In addition, no MMP-2
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increase was found in CIP; therefore a constitutive role for
this enzyme remains likely.
Inmen, increases inTIMP-1 andTIMP-2 have been found
in asthma and COPD. Results of the presented study show
that the same is true for equine RAO and IAD, but not
for CIP. This makes sense, as CIP represents the final stage
of interstitial pneumonia, characterized by a low grade of
inflammation and organized fibrotic tissue. High correlations
of MMPs as well as TIMPs with clinical findings and BALF
cytology over all horses substantiate this result. Despite
these obviously clear results, MMP : TIMP ratios raised our
special interest, as they show a possible disbalance between
ECM degradation and repair mechanisms leading to either
pulmonary tissue destruction or fibrosis formation in the end.
Perhaps the most interesting one was the MMP-8 : TIMP-
1 ratio, in which significant differences were found for all
pneumopathies studied compared to healthy controls, but
in different orientations. While RAO was characterized by
predominating collagenolytic activity demonstrated by an
increased ratio, IAD/RAO in remission and CIP were char-
acterized by predominating fibrosis formation demonstrated
by a decreased ratio. This shows that even forms of equine
respiratory disease going along with very slight clinical signs
and cytologic findings lead to fibrosis formation affecting
prognosis in these patients. Additionally, theMMP-8 : TIMP-
1 ratio can identify cases of respiratory disease, in which
clinical signs and cytologic findings are almost unremarkable,
which is very helpful, when examining horses in remission.
EquineRAOshows features of human asthma andCOPD.
While the recurrent character of the disease resembles
asthma, long-term changes include irreversible remodeling
of the bronchial wall leading to decreased gas exchange
and pulmonary function as known for COPD. In asthma,
the degree of MMP activity can be linked to intensity of
the inflammatory processes in the airways; therefore the
MMPs/TIMPs balance is widely accepted to have a role in
the pathogenesis of airflow limitation and reflect the extent of
structural changes in the lung [39–41]. Mediators released by
activated parenchymal and inflammatory cells could induce
MMPs secretion and activation, increase in MMP-9 activity,
and elevated MMP-9/TIMP-1 ratios as demonstrated in mild
asthma after allergen challenge in sputum and BALF [23, 42].
Specific allergen challenge is also able to induce changes in
MMPs and TIMPs, in particular MMP-9, in occupational
asthma [43]. In severe asthma, increased basal levels ofMMP-
9 were even observed in plasma [44]. No difference was also
found for MMP-2, again supporting a constitutive role as
discussed earlier.
Equine RAO also shows features of human COPD, in
which long-term exposure to cigarette smoke, toxic gases, and
particulate matter leads to airflow limitation and pulmonary
failure [39]. As RAO the disease is characterized by an excess
of extracellular matrix deposition in bronchial walls, known
as remodeling and involving many members of the MMP
family, chronic cough, and dyscrasia. Increased MMP-1 and
MMP-9 levels have been detected in BALF of emphysema
patients [38]. COPD patients show increased activities of
MMP-2 and MMP-9 in their lung parenchyma [45] and
increased gelatinolytic activity linked toMMP-2 andMMP-9
in their sputum [46, 47]. An increase of collagenolytic
activity, probably due to elevated levels of MMP-8, was also
found [48].
Chronic interstitial pneumopathy is a poorly defined
disease in equine medicine. Descriptions in the literature are
rare [49]. Dieckmann et al. [30] gave some definition criteria
from the examination of 12 affected patients and Venner et al.
[50] studied horses after experimental induction of acute
interstitial pneumopathy. In the early stage of human lung
fibrosis, gelatinolytic activity of MMP-9 seems predominant
and probably contributes to disruption of alveolar epithelial
basement membrane and enhances fibroblast invasion to
alveolar spaces [39], while, in the late stages of the disease,
MMP-2 seems to become predominant. The expression of
the two gelatinases at different stages of fibrosis suggests
that MMP-9 could be rather linked to inflammation-induced
tissue remodeling, while MMP-2 may be associated with an
impaired tissue remodeling leading to pathological collagen
deposition and interstitial fibrosis [41].
A weak point of this study was group definition, as
samples were obtained from clinic patients. Although IAD
and RAO in remission were planned as two distinct groups,
it was not possible to differentiate clearly between these two.
Anamnestic information of respiratory distress was often
unreliable and the majority of owners did not agree to a
natural challenge test. Descriptions of equine CIP are rare
in the literature and an international consensus statement is
missing, so definition of this group was based on a quite old
clinical case series including only 12 horses [30]. Thoracic
radiography showing interstitial patterns is not very specific
for CIP and may also be found in RAO [51] and IAD
[52]. Again, the majority of owners did not agree to lung
biopsies. We tried to face these problems by calculating
correlations between MMPs and TIMPs with clinical and
cytologic parameters over all 61 horses and found significant
results for almost all correlations, demonstrating the value
of MMPs, TIMPs, and MMP : TIMP ratios as biomarkers
independent of diagnosis.
In conclusion, metalloproteinases and their inhibitors,
in particular MMP-9 and TIMP-1, are increased in different
chronic pneumopathies in the horse and correlate signifi-
cantly with clinical and cytologic findings. MMPs, TIMPs,
and in particular the MMP-8 : TIMP ratios are useful to
evaluate the severity and character of respiratory disease
and may have prognostic value for equine pneumopathies.
Further studies should focus on the balance between MMPs
and TIMPs and their progression during disease and possible
improvement during therapy.
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